Skip to content
OpenCapital
Get started

Relmada Therapeutics, Inc. RLMD Pre-tax stock-based compensation cost

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$677.17M+2,907%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Debt / equity0.9×0.0×
Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s pre-tax stock-based compensation cost.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s pre-tax stock-based compensation cost?
Relmada Therapeutics, Inc. (RLMD) reported pre-tax stock-based compensation cost of $956.2K in Q1 2026.
How has Relmada Therapeutics, Inc.'s pre-tax stock-based compensation cost changed year-over-year?
Relmada Therapeutics, Inc.'s pre-tax stock-based compensation cost decreased by 73.2% year-over-year, from $3.57M to $956.2K.
What is the long-term trend for Relmada Therapeutics, Inc.'s pre-tax stock-based compensation cost?
Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s pre-tax stock-based compensation cost has grown at a -22.2% compound annual growth rate (CAGR), from $40.49M to $14.81M.